DOCSLIB.ORG

Développement De Modèles Prédictifs De La Toxicocinétique De Substances Organiques

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Développement De Modèles Prédictifs De La Toxicocinétique De Substances Organiques Université de Montréal Développement de modèles prédictifs de la toxicocinétique de substances organiques par Thomas Peyret Département de santé environnementale et santé au travail Faculté de Médecine Thèse présentée à la Faculté de Médecine en vue de l’obtention du grade de Ph.D. en Santé Publique option Toxicologie et analyse du risque Février, 2013 © Peyret, 2013 Université de Montréal Faculté des études supérieures et postdoctorales Cette thèse intitulée : Développement de modèles prédictifs de la toxicocinétique de substances organiques Présentée par : Thomas Peyret a été évaluée par un jury composé des personnes suivantes : Marc Baril, président-rapporteur Kannan Krishnan, directeur de recherche Ginette Truchon, membre du jury Yumei Cecilia Tan, examinateur externe Patrick du Souich, représentant du doyen de la FESP Résumé Les modèles pharmacocinétiques à base physiologique (PBPK) permettent de simuler la dose interne de substances chimiques sur la base de paramètres spécifiques à l’espèce et à la substance. Les modèles de relation quantitative structure-propriété (QSPR) existants permettent d’estimer les paramètres spécifiques au produit (coefficients de partage (PC) et constantes de métabolisme) mais leur domaine d’application est limité par leur manque de considération de la variabilité de leurs paramètres d’entrée ainsi que par leur domaine d’application restreint (c. à d., substances contenant CH3, CH2, CH, C, C=C, H, Cl, F, Br, cycle benzénique et H sur le cycle benzénique). L’objectif de cette étude est de développer de nouvelles connaissances et des outils afin d’élargir le domaine d’application des modèles QSPR-PBPK pour prédire la toxicocinétique de substances organiques inhalées chez l’humain. D’abord, un algorithme mécaniste unifié a été développé à partir de modèles existants pour prédire les PC de 142 médicaments et polluants environnementaux aux niveaux macro (tissu et sang) et micro (cellule et fluides biologiques) à partir de la composition du tissu et du sang et de propriétés physicochimiques. L’algorithme résultant a été appliqué pour prédire les PC tissu:sang, tissu:plasma et tissu:air du muscle (n = 174), du foie (n = 139) et du tissu adipeux (n = 141) du rat pour des médicaments acides, basiques et neutres ainsi que pour des cétones, esters d’acétate, éthers, alcools, hydrocarbures aliphatiques et aromatiques. Un modèle de relation quantitative propriété-propriété (QPPR) a été développé pour la clairance intrinsèque (CLint) in vivo (calculée comme le ratio du Vmax (μmol/h/kg poids de rat) sur le Km (μM)), de substrats du CYP2E1 (n = 26) en fonction du PC n-octanol:eau, du PC sang:eau et du potentiel d’ionisation). Les prédictions du QPPR, représentées par les limites inférieures et supérieures de l’intervalle de confiance à 95% à la moyenne, furent ensuite intégrées dans un modèle PBPK humain. Subséquemment, l’algorithme de PC et le QPPR pour la CLint furent intégrés avec des modèles QSPR pour les PC hémoglobine:eau et huile:air pour simuler la pharmacocinétique et la dosimétrie cellulaire d’inhalation de composés organiques volatiles (COV) (benzène, 1,2-dichloroéthane, dichlorométhane, m-xylène, toluène, styrène, i 1,1,1-trichloroéthane et 1,2,4-trimethylbenzène) avec un modèle PBPK chez le rat. Finalement, la variabilité de paramètres de composition des tissus et du sang de l’algorithme pour les PC tissu:air chez le rat et sang:air chez l’humain a été caractérisée par des simulations Monte Carlo par chaîne de Markov (MCMC). Les distributions résultantes ont été utilisées pour conduire des simulations Monte Carlo pour prédire des PC tissu:sang et sang:air. Les distributions de PC, avec celles des paramètres physiologiques et du contenu en cytochrome P450 CYP2E1, ont été incorporées dans un modèle PBPK pour caractériser la variabilité de la toxicocinétique sanguine de quatre COV (benzène, chloroforme, styrène et trichloroéthylène) par simulation Monte Carlo. Globalement, les approches quantitatives mises en œuvre pour les PC et la CLint dans cette étude ont permis l’utilisation de descripteurs moléculaires génériques plutôt que de fragments moléculaires spécifiques pour prédire la pharmacocinétique de substances organiques chez l’humain. La présente étude a, pour la première fois, caractérisé la variabilité des paramètres biologiques des algorithmes de PC pour étendre l’aptitude des modèles PBPK à prédire les distributions, pour la population, de doses internes de substances organiques avant de faire des tests chez l’animal ou l’humain. Mots-clés : Toxicocinétique, Modélisation pharmacocinétique à base physiologique, Relation quantitative structure-propriété, Relation quantitative propriété-propriété, Simulation Monte Carlo, Monte Carlo par chaîne de Markov, Coefficient de partage, Métabolisme, Analyse d’incertitude, Dosimétrie cellulaire. ii Abstract Physiologically-based pharmacokinetic (PBPK) models simulate the internal dose metrics of chemicals based on species-specific and chemical-specific parameters. The existing quantitative structure-property relationships (QSPRs) allow to estimate the chemical- specific parameters (partition coefficients (PCs) and metabolic constants) but their applicability is limited by their lack of consideration of variability in input parameters and their restricted application domain (i.e., substances containing CH3, CH2, CH, C, C=C, H, Cl, F, Br, benzene ring and H in benzene ring). The objective of this study was to develop new knowledge and tools to increase the applicability domain of QSPR-PBPK models for predicting the inhalation toxicokinetics of organic compounds in humans. First, a unified mechanistic algorithm was developed from existing models to predict macro (tissue and blood) and micro (cell and biological fluid) level PCs of 142 drugs and environmental pollutants on the basis of tissue and blood composition along with physicochemical properties. The resulting algorithm was applied to compute the tissue:blood, tissue:plasma and tissue:air PCs in rat muscle (n = 174), liver (n = 139) and adipose tissue (n = 141) for acidic, neutral, zwitterionic and basic drugs as well as ketones, acetate esters, alcohols, ethers, aliphatic and aromatic hydrocarbons. Then, a quantitative property-property relationship (QPPR) model was developed for the in vivo rat intrinsic clearance (CLint) (calculated as the ratio of the in vivo Vmax (μmol/h/kg bw rat) to the Km (μM)) of CYP2E1 substrates (n = 26) as a function of n-octanol:water PC, blood:water PC, and ionization potential). The predictions of the QPPR as lower and upper bounds of the 95% mean confidence intervals were then integrated within a human PBPK model. Subsequently, the PC algorithm and QPPR for CLint were integrated along with a QSPR model for the hemoglobin:water and oil:air PCs to simulate the inhalation pharmacokinetics and cellular dosimetry of volatile organic compounds (VOCs) (benzene, 1,2-dichloroethane, dichloromethane, m-xylene, toluene, styrene, 1,1,1-trichloroethane and 1,2,4-trimethylbenzene) using a PBPK model for rats. Finally, the variability in the tissue and blood composition parameters of the PC algorithm for rat tissue:air and human iii blood:air PCs was characterized by performing Markov chain Monte Carlo (MCMC) simulations. The resulting distributions were used for conducting Monte Carlo simulations to predict tissue:blood and blood:air PCs for VOCs. The distributions of PCs, along with distributions of physiological parameters and CYP2E1 content, were then incorporated within a PBPK model, to characterize the human variability of the blood toxicokinetics of four VOCs (benzene, chloroform, styrene and trichloroethylene) using Monte Carlo simulations. Overall, the quantitative approaches for PCs and CLint implemented in this study allow the use of generic molecular descriptors rather than specific molecular fragments to predict the pharmacokinetics of organic substances in humans. In this process, the current study has, for the first time, characterized the variability of the biological input parameters of the PC algorithms to expand the ability of PBPK models to predict the population distributions of the internal dose metrics of organic substances prior to testing in animals or humans. Keywords : Toxicokinetics, Physiologically based pharmacokinetic modeling, Quantitative structure-property relationship, Quantitative property-property relationship, Monte Carlo simulation, Markov chain Monte Carlo, Partition coefficient, Metabolism, Uncertainty analysis, Cellular dosimetry. iv Table des matières Résumé .................................................................................................................................... i Abstract ................................................................................................................................. iii Table des matières .................................................................................................................. v Liste des tableaux ................................................................................................................... x Liste des figures .................................................................................................................. xiii Abréviations ........................................................................................................................ xvi Chapitre 1. Introduction générale ..................................................................................... 1 1.1. La modélisation QSAR pour les modèles pharmacocinétiques
Load more

Recommended publications
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Veterinary Anaesthesia (Tenth Edition)
    W. B. Saunders An imprint of Harcourt Publishers Limited © Harcourt Publishers Limited 2001 is a registered trademark of Harcourt Publishers Limited The right of L.W. Hall, K.W. Clarke and C.M. Trim to be identified as the authors of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without either the prior permission of the publishers (Harcourt Publishers Limited, Harcourt Place, 32 Jamestown Road, London NW1 7BY), or a licence permitting restricted copying in the United Kingdom issued by the Copyright Licensing Agency Limited, 90 Tottenham Court Road, London W1P 0LP. First edition published in 1941 by J.G. Wright Second edition 1947 (J.G. Wright) Third edition 1948 (J.G. Wright) Fourth edition 1957 (J.G. Wright) Fifth edition 1961 (J.G. Wright and L.W. Hall) Sixth edition 1966 (L.W. Hall) Seventh edition 1971 (L.W. Hall), reprinted 1974 and 1976 Eighth edition 1983 (L.W. Hall and K.W. Clarke), reprinted 1985 and 1989 Ninth edition 1991 (L.W. Hall and K.W. Clarke) ISBN 0 7020 2035 4 Cataloguing in Publication Data: Catalogue records for this book are available from the British Library and the US Library of Congress. Note: Medical knowledge is constantly changing. As new information becomes available, changes in treatment, procedures, equipment and the use of drugs become necessary. The authors and the publishers have taken care to ensure that the information given in this text is accurate and up to date.
    [Show full text]
  • Effects of Chronic Treatment with Testosterone Propionate on Aggression and Hormonal Levels in Intact Male Mice
    Psychoneuroendocrinology, Vol. 23, No. 3, pp. 275–293, 1998 © 1998 Elsevier Science Ltd. All rights reserved Printed in Great Britain 0306-4530/98 $19.00+.00 PII: S0306-4530(97)00005-5 EFFECTS OF CHRONIC TREATMENT WITH TESTOSTERONE PROPIONATE ON AGGRESSION AND HORMONAL LEVELS IN INTACT MALE MICE S. Martı´nez-Sanchis, A. Salvador, L. Moya-Albiol, E. Gonza´lez-Bono and V. M. Simo´n Area de Psicobiologı´a, Facultad de Psicologı´a, Universitat de Vale`ncia, Avenida Blasco Iban˜ez n° 21, Apartado 22109, 46071 Valencia, Spain (Recei6ed 31 January 1997; in final form 22 No6ember 1997) SUMMARY Effects of testosterone propionate, an anabolic-androgenic steroid (AAS), on aggression in gonadally intact male mice were examined. Animals were given weekly injections of 3.75, 7.5, 15, and 30 mg/kg of drug or sesame oil for 10 weeks. During the last 3 weeks, behavioral tests were conducted and at the end of the experiment, body, liver and testes weight and hormonal data were collected. The treatment had minimal behavioral and endocrine effects. It resulted in shorter latencies of ‘threat’ only in the last agonistic encounter, increases in testosterone levels and decreases in testes weight in a non-linear dose-dependant way. The action of the treatment was different on threat and attack, the latter being unaffected. The behavioral effects in the total sample were only found in aggressive animals selected on the basis of their latency of attack in the first encounter. © 1998 Elsevier Science Ltd. All rights reserved. Keywords—AAS; Testosterone; Corticosterone; Aggression; Intact male mice; Individual differences.
    [Show full text]
  • Un Novedoso Enfoque Para El Diseño De Fármacos Antimicrobianos Asistido Por Computadora
    TOMOCOMD-CARDD: Un Novedoso Enfoque para el Diseño de Fármacos Antimicrobianos Asistido por Computadora Autora: Yasnay Valdés Rodríguez. Tutores: Prof. Dr. Yovani Marrero Ponce. Prof. MSc. Ricardo Medina Marrero. 2005-2006 La ignorancia afirma o niega rotundamente; la ciencia duda… Voltaire (1694-1778) Quiero dedicar este trabajo a todas aquellas personas que me aprecian y desean lo mejor para mi, especialmente a mis padres. A mi padre Dedico este trabajo con mucho amor, por hacerme comprender que siempre se puede llegar mas lejos, y que no hay nada imposible, solamente hay que luchar... A mi madre Por su infinita bondad, por su sacrificio inigualable. A mis familiares Por todo su apoyo y ayuda que me han mostrado incondicionalmente. A mi hermano Por ser mi fuente de inspiración. A la humanidad “...porque si supiera que el mundo se acaba mañana, yo, hoy todavía, plantaría un árbol” Quiero agradecer a todas aquellas personas que me han ayudado a realizar este sueño: A mis padres por todo el sacrificio realizado, y aún parecerles poco, los amo mucho. A mi madre por estar siempre a mi lado en los buenos y malos momentos ayudándome a levantarme en cualquier recaída. A mi padre por guiarme en la vida y brindarme sus consejos siempre útiles, por darme fuerza y vitalidad. A mi mayor tesoro, mi hermano, que me alumbra de esperanza día a día. A mis tías y primos que me ayudaron mucho, aún estando lejos. A mi novio que me apoyo en todas mis decisiones y con paciencia supo ayudarme. A mis tutores y cotutores que siempre me dieron la mano; especialmente a Yovani por su paciencia, a quien debo gran parte de mi formación como profesional por sus exigencias.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Xerox University Microfilms
    INFORMATION TO USERS This material was produced from a microfilm copy of the original document. While the most advanced technological means to photograph and reproduce this document have been used, the quality is heavily dependent upon the quality of the original submitted. The following explanation of techniques is provided to help you understand markings or patterns which may appear on this reproduction. 1.The sign or "target" for pages apparently lacking from the document photographed is "Missing Page(s)". If it was possible to obtain the missing page(s) or section, they are spliced into the film along with adjacent pages. This may have necessitated cutting thru an image and duplicating adjacent pages to insure you complete continuity. 2. When an image on the film is obliterated with a large round black mark, it is an indication that the photographer suspected that the copy may have moved during exposure and thus cause a blurred image. You will find a good image of the page in the adjacent frame. 3. When a map, drawing or chart, etc., was part of the material being photographed the photographer followed a definite method in "sectioning" the material. It is customary to begin photoing at the upper left hand corner of a large sheet and to continue photoing from left to right in equal sections with a small overlap. If necessary, sectioning is continued again — beginning below the first row and continuing on until complete. 4. The majority of users indicate that the textual content is of greatest value, however, a somewhat higher quality reproduction could be made from "photographs" if essential to the understanding of the dissertation.
    [Show full text]
  • Central Nervous Systems’ Effects of Isoflurane
    CENTRAL NERVOUS SYSTEMS' EFFECTS OF ISOFLURANE (FORANE) EVA M. KAVAN, M.D. AND ROBERT M. JULIEN, PH.D. INTRODUCTION [SOFLUBANE (Forane,* 1-chloro-2,2,2,-trifluoroethyl difluoromethyl ether (is a re- cently developed short-chain halogenated inhalation agent. It is an isomer of enflu- rane, with a different boiling point and vapour pressure? Isoflurane provides rapid induction as well as prompt emergence from anaesthesia. Isoflurane-induced an- aesthesia has been investigated in experimental animals 2-4 and in man. ~-8 Its effects on the cortical EEG have been determined in dogs, 4 in human volunteers 7 and in patients during operations. 8 However, the effects of isoflurane on subcortical struc- tures have not been investigated. The present study was conducted to supply these data. METHODS A. Chronic Experiments Five cats (average weight 4.8 kg) were used in eight experiments. Under pento- barbital anaesthesia, using sterile technique, bipolar concentric stainless steel elec- trodes (0.2 mm diameter) were implanted stereotaxically9 into the following struc- tures: 11. caudatus (CAUD), n. ventralis postero-lateralis (primary relay nucleus) of the thalamus (VPL), the midbrain reticular formation (RF), n. centrum medi- anum (CM), n. amygdalae (AMYG) and formatio hippocampi (HIPP). Stainless steel screws were imbedded in the skull over frontal and parietal cortices. Leads from all electrodes were soldered to miniature Winchester sockets which were secured to the skull with acrylic resin. Two weeks after implantation, the cats were taken to the laboratory for condi- tioning and control tracings. In the following week, isoflurane vapourized through a copper kettle was administered by mask, using a total of 1 L/rain flow of equal parts of air and oxygen in a semiclosed system.
    [Show full text]
  • De Fármacos Antimaláricos
    Facultad de Química-Farmacia Centro de Bioactivos Químicos TOMOCOMD-CARDD: Un Novedoso Enfoque para el Diseño ‘Racional In- Silico’ de Fármacos Antimaláricos Tesis presentada en opción al grado de Licenciado en Ciencias Farmacéuticas. Autor: Carlos Ricardo Romero Zaldivar Tutores: Prof. Inst., Lic. Yovani Marrero Ponce, M.Sc. Prof. Asist., Lic. Maité Iyarreta Veitía, Ph.D. Santa Clara 2004 RESUMEN Nuevos descriptores moleculares útiles para el diseño “racional in silico” de fármacos han sido aplicados a la modelación de la actividad antimalárica. El cálculo de los nuevos índices moleculares fue implementado en el programa TOMOCOMD-CARDD (TOpological MOlecular COMputer Design-Computed Aided ‘Rational’ Drug Design). Los índices cuadráticos y lineales (estocásticos y no estocásticos) fueron usados junto con el análisis discriminante lineal (ADL) para desarrollar modelos QSAR-ADL que permitan la correcta predicción de la actividad antimalárica. Los modelos obtenidos describen adecuadamente la actividad biológica estudiada y en todos los casos clasifican correctamente más del 90.00% de los compuestos en la serie de entrenamiento. En orden de acceder a la robustez y al poder predictivo de los modelos encontrados, procedimientos de validación cruzada interna y externa fueron utilizados. Estas aproximaciones permiten obtener una adecuada explicación de la actividad antimalárica basado en rasgos estructurales evidenciando el rol preponderante de los enlaces de hidrógenos, la presencia de heteroátomos y de las propiedades relacionadas con el tamaño molecular en las interacciones con los sitios dianas antimaláricos. Posteriormente, los modelos desarrollados fueron usados en la simulación de una búsqueda virtual de inhibidores de la farnesil-transferasa (H-Ras) con actividad antimalárica; 84.61% de los inhibidores de la H-Ras usados en esta búsqueda virtual fueron correctamente clasificados por las modelos QSAR-ADL, indicando la habilidad del método TOMOCOMD-CARDD para el descubrimiento de nuevos compuestos líderes con nuevos mecanismos de acción.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]